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Tea polyphenols known as catechins are key components with many biological functions, including anti-inﬂammatory,
antioxidative, and anticarcinogenic eﬀects. These eﬀects are induced by the suppression of several inﬂammatory factors including
nuclear factor-kappa B (NF-κB). While these characteristics of catechins have been well documented, actions of catechins as
mediators on inﬂammation-related cardiovascular diseases have not yet been well investigated. In this article, we reviewed
recent papers to reveal the anti-inﬂammatory eﬀects of catechins in cardiovascular diseases. In our laboratory, we performed
oral administration of catechins into murine and rat models of cardiac transplantation, myocarditis, myocardial ischemia, and
atherosclerosis to reveal the eﬀects of catechins on the inﬂammation-induced ventricular and arterial remodeling. From our
results, catechins are potent agents for the treatment and prevention of inﬂammation-related cardiovascular diseases because
they are critically involved in the suppression of proinﬂammatory signaling pathways.
Copyright © 2009 Jun-ichi Suzuki et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Green tea is known to prevent cardiovascular diseases; tea
consumption is known to be associated with lower mortality
of clinical myocardial infarction [1, 2]. It has been reported
that green tea consumption reduced cardiovascular disease
mortality in the Japanese population [3–5]. Catechins are
important components of green tea with many biological
functions, including anti-inﬂammatory, antioxidative, and
anticarcinogenic eﬀects [6–9]. These eﬀects are induced by
the suppression of several inﬂammatory factors including
n u c l e a rf a c t o r - k a p p aB( N F - κB), a multipotential pro-
moter of matrix metalloproteinases (MMPs), cytokines,
and adhesion molecules [10]. The major tea catechins
are epigallocathechin-3 gallate (EGCG), epigallocathechin
(EGC), epicathechin-3 gallate (ECG). While these charac-
teristics of tea catechins have been well documented [11],
their eﬀects on inﬂammatory cardiovascular diseases have
not been well investigated. Recently, we have reported the
eﬀects of tea catechins on myocardial ischemia [12], acute
myocarditis [13], heart transplantation [14], and atheroscle-




Cardiac transplantation has been established to treat end-
stage heart failure, however acute rejection and graft arterial
diseases (GADs) are still problems [16–19]. We have revealed
that NF-kB plays a key role in the progression of cardiac
allograft rejection. To conﬁrm the eﬀects of catechins on
rejection, we have used a class II allomismatch combination
of the mice to perform cardiac transplantation [20]. The
transplanted mice were assigned randomly to two groups.2 Mediators of Inﬂammation
The recipient mice were orally supplemented with tea cate-
chins(20mg/kg/day,THEA-FLAN90S(Ito-enCo.Shizuoka,
Japan) which includes EGCG: 45.2% ECG: 13.7% EGC:
0.23%) daily. This ratio is the natural dose ratio in the
extracts from green tea. For control, transplanted mice were
supplemented with normal water without the catechins.
Although severe myocardial cell inﬁltration and ﬁbro-
sis was observed in nontreated allografts at day 60, tea
catechins markedly attenuated myocardial cell inﬁltration
and ﬁbrosis. Immunohistochemically, enhancement of CD4,
CD8, CD11b, intercellular adhesion molecule (ICAM)-1,
and vascular cell adhesion molecule (VCAM)-1 expres-
sion was observed in nontreated allograft myocardium,
inﬁltrating cells and coronary arteries. However, catechin
markedly attenuated expression of all these factors. RNase
protection assay was employed to examine expression of
cytokine mRNA in hearts. Levels of Th2 cytokine IL-10 was
signiﬁcantlyelevatedinthecatechin-treatedgroupcompared
with that of nontreated group. To prove the eﬀect of
catechins on NF-κB, we performed a gel mobility shift assay
using the EMSA kit. The analysis documented that catechin
administration reduced NF-κB binding activity (Figure 1)
[14]. In the study, we have demonstrated that tea catechins
reduced both myocardial remodeling and GAD formation
with altered several inﬂammatory factors via suppression of
NF-κB binding activity. Because blockade of NF-κB binding
activity results in suppression of cell adhesion molecules, the
factorsarecriticalintransplantationbecausetheycaninduce
immunological tolerance [21–24]. Therefore, regulation of
NF-κB binding activity by catechins is clinically eﬀective for
suppression of transplant rejection.
Recently, Tripathi et al. demonstrated that green tea
extract (GTE) in combination with low dose CyA sig-
niﬁcantly prolongs graft survival as well as increase the
production of immunosuppressive cytokines in the murine
model of nonvascularized cardiac allografts. They concluded
that the potential of GTE as an adjunctive therapy in
combination with CyA to prolong allograft survival and to
reduce CyA induced nephrotoxicity [25].
3.CatechinsRegulate MMPs in
MyocardialIschemia
Myocardial ischemia and ventricular remodeling causes
signiﬁcant damage leading to severe heart failure. It has
been known that NF-κB related inﬂammation is enhanced
by ischemia and reperfusion of myocardium; the activated
NF-κB induces MMPs. Thus, decoy against NF-κBr e d u c e s
myocardial inﬂammation induced by ischemia/reperfusion
injury [26]. Since MMPs are key components in the positive
feedback loop of heart remodeling, the inhibition is an
eﬀective therapy for myocardial reperfusion injury [27–
30]. It is also well known that catechins suppress several
inﬂammatory factors including MMPs induced by NF-κB
[10]. To clarify the role of catechins on the ischemic hearts,
we made a rat myocardial ischemia model by ligation
of the left anterior descending coronary artery and this








Figure 1: Gel mobility shift assay of cardiac transplantation.Gel
mobility shift assay documented that increased NF-κκB binding
activity was observed in nontreated allografts. This enhanced NF-
κB binding was reduced by catechin administration (20 mg/kg/day,
THEA-FLAN 90S).
Catechin Non-treated Native
MMP-2 (gelatinase A) 72 kb
MMP-9 (gelatinase B) 95 kb
Figure 2: Zymography of myocardial ischemia. Gelatin zymography
showed that increased gelatinase (MMP-2 and MMP-9) activity was
observedinheartsinthenon-treatedischemia group.However, this
enhanced gelatinase activity was decreased by catechin administra-
tion (20 mg/kg/day, THEA-FLAN 90S).
nontreated ischemia group showed signiﬁcant decline of
blood pressure compared to non-treated sham-operated
group. However, the catechin (20mg/kg/day, THEA-FLAN
90S) administration suppressed the decline of the blood
pressure compared to that of non-treated ischemia group
on days 14 and 21. Pathologically, the anterior wall of
the hearts was completely ﬁbrotic and remaining area
showed interstitial ﬁbrosis and cell inﬁltration. However,
catechin-treated hearts showed signiﬁcantly less infarct
size, infarct length, left ventricular circumference, and
left ventricular inner diameter than those in the non-
treated ischemia group. Immunohistochemically, increased
numbers of CD4, CD8, CD11b ICAM-1, and ED-1 pos-
itive inﬁltrating cells were observed in the non-treated
ischemia group, while the catechin administration sup-
pressed the numbers signiﬁcantly. Finally, to reveal the
role of MMPs, the infarct region and myocardium were
separated under a dissecting microscope and they were
used zymography as previously reported. This showed
that increased gelatinase (MMP-2 and MMP-9) activ-
ity was observed in hearts in the non-treated ischemia
group. However, this enhanced gelatinase activity was
decreased by catechin administration (Figure 2). In sum-
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Figure 3: RNase protection assay of myocarditis. TNF-alpha mRNA level was markedly decreased in the catechin treated group compared
with that of control group. On the other hand, mRNA levels of Th2 cytokines such as IL-4 and IL-10 in the catechin treated group (20





Figure 4: Immunohistochemistry of atherosclerosis. Panels show representative immunohistochemical ﬁndings. VCAM-1 expression was
enhanced in the aortic walls of non-treated LDLRKO mice. However, catechin administration (2% THEA-FLAN 90S contained high fat
chaw) suppressed the expression in the organs of LDLRKO mice.
prevented ventricular remodeling after ischemic injury due




Myocarditis is a serious disease in clinical settings, patients
with myocarditis may present with rapidly progressive heart
failure, shock, or arrhythmia. Although acute myocardial
inﬂammation is an essential etiology for the progression,
any established treatment has not yet been elucidated [31–
35]. Experimental autoimmune myocarditis (EAMs) is a
rat model that is characterized by myocardial damages and
multinucleated giant cell inﬁltration. This has been used as a
diseasemodelofhumanacutemyocarditis[36–40].Toclarify
the eﬀects of catechins on myocarditis, we administered the
catechins (20mg/kg/day, THEA-FLAN 90S) to rats after the
induction of EAM. We found that the catechins signiﬁcantly
reduced the heart weight/body weight ratio compared to
that of non-treated EAM controls. Echocardiogram revealed
the catechins improved the cardiac function compared
to the controls. Pathologically, non-treated control EAM
animals showed severe myocardial cell inﬁltration and
ﬁbrotic lesions. However, the catechin treatment showed
signiﬁcantly less myocardial cell inﬁltration and ﬁbrosis
areas compared to those in controls. Immunohistochemistry
revealed that enhanced expression of CD4, CD8, CD11b,
ICAM-1, and NF-κB on inﬁltrating and arterial endothelial
cells was observed in non-treated EAM hearts, while the
catechins suppressed the expression. To examine expression
of cytokine mRNA in EAM hearts, RNase protection assay
was used. TNF-alpha mRNA level was markedly decreased
in the catechin-treated group compared with that of control
group. On the other hand, mRNA levels of Th2 cytokines
such as IL-4 and IL-10 in the catechin-treated group were
markedly enhanced compared with that of control group
(Figure 3). We revealed that the myocardial cell inﬁltration,
ﬁbrosis, proinﬂammatory cytokines were enhanced in the4 Mediators of Inﬂammation
EAM progression and the catechins suppressed the develop-
ment of these changes with altered cytokine expression [13].
5. CatechinsAlteredAdhesion Molecules and
Nitric Oxide
To evaluate the eﬀects of tea catechins for the development
of atherosclerosis induced by hyperlipidemia, we admin-
istered catechins (2 or 4% THEA-FLAN 90S contained
high fat chaw) to LDL receptor knockout (LDLRKO)
mice. Immunohistocemically, VCAM-1, a critical adhesion
molecule for vascular diseases, expression was enhanced in
the endothelial cells, smooth muscle cells, and inﬁltrating
cells in the aortic walls of LDLRKO mice. However, catechin
administration signiﬁcantly suppressed VCAM-1 expression
in the atherosclerotic lesions in LDLRKO mice, although
LDLRKO mice with the 2% catechins showed comparable
cholesterol levels (Figure 4)[ 15]. In the study, catechins
prevent the development with or without changing the
plasma lipid levels in the animals through the suppression
of adhesion molecules. Babu and Lie reviewed that catechins
have further eﬀects on cell adhesion molecules. They showed
thatcatechinspreventvascularinﬂammationviasuppression
of leukocyte adhesion to endothelium and subsequent
transmigration through inhibition of transcriptional factor
NF-κB-mediated production of adhesion molecules both in
endothelial cells and inﬂammatory cells [41].
Nitric oxide (NO) is an important molecule that plays a
pivotal role in inﬂammatory conditions of hearts, and many
papers showed interesting data. Babu and Liu demonstrated
thatcatechinsregulatevasculartonebyactivatingendothelial
NO [41]. Paquay et al. revealed that the catechins are
potent peroxynitrite scavengers and are eﬀective inhibitors
of inducible NO synthase (iNOS) [42]. Agnetti et al. also
evaluated that GTE supplementation counteracted on iNOS
inductionandactivityincardiomyocytes[43].Itisalsonote-
worthy that EGCG inhibits endothelial exocytosis, the initial




We have demonstrated that the catechin intake signiﬁcantly
suppresses the expression of inﬂammatory factors including
adhesion molecules, cytokines, and MMPs. These key factors
are known to be regulated by NF-κB, which is a central
mediator for the development of inﬂammatory diseases. We
have reported speciﬁc inhibition of NF-κB using a decoy in
the myocardial ischemia [26], myocarditis [36], and heart
transplant rejection [45]. In these studies, the NF-κBd e c o y
suppresses many inﬂammatory factors including adhesion
molecules,cytokines,andMMPs.Althoughcatechinsarenot
speciﬁc inhibitors of NF-κB, they have similar eﬀects to the
inhibitors such as suppression of adhesion molecules and
other inﬂammatory factors. Therefore, catechins have the
potential to suppress clinical inﬂammatory diseases.
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